DeCure for Brachydactyly-arterial hypertension syndrome
DeCure's autonomous Cardio AI scientist is researching a drug-repurposing hypothesis for brachydactyly-arterial hypertension syndrome — screening already-approved drugs against its 1-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleBrachydactyly-arterial hypertension syndrome maps to a 1-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for brachydactyly-arterial hypertension syndrome is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
phosphodiesterase 3A (PDE3A) — PDE3A is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet 5r,6pdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 7LRC · 2.97 Å · ligand (5R,6P)-6-[4-(diethylamino)-3-nitrophenyl]-5-methyl-4,5-dihydropyridazin-3(2H)-one (X5M). Experimental structure, not a prediction.
What the evidence adds up to
A 1973 report described a family in which brachydactyly and hypertension appeared together, with the pattern suggesting a single autosomal dominant gene or two closely linked genes. The authors considered this a previously undescribed entity. No further genetic or mechanistic detail was provided, and no treatment was discussed in that paper.
The remaining abstracts concern general arterial hypertension, not the brachodactyly‑hypertension syndrome. A 2022 review of a century of textbook chapters on primary hypertension identified three eras of drug treatment: empiric sedation (1927‑1947), ganglion blockers and vasodilators (1955‑1963), and modern agents including diuretics, beta‑blockers, calcium channel blockers, ACE inhibitors, and angiotensin receptor blockers (1967‑2020). A 2021 review noted that despite effective drugs, many patients still have uncontrolled blood pressure and that new pharmacological and technological strategies are under development. A 1966 paper stated that normal or near‑normal blood pressure could be achieved with available drugs but that both physicians and patients needed better training.
No abstract reports any drug tested specifically in brachydactyly‑arterial hypertension syndrome. No trial, no survival data, no response rates, and no sample sizes for this condition appear in the provided literature. What is missing is any clinical trial, any genetic stratification of patients, and any funding directed at this specific syndrome rather than at essential hypertension in general.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Journal of Medical Genetics · 1973 · 92 citations · open access
Hereditary Brachydactyly Associated with Hypertension
AbstractA family showing brachydactyly associated with hypertension is reported. The number and location of the involved bones are quite different from the other cases with brachydactyly reported in the literature. Additionally, all our patients have high blood pressure. We believe that the disorder reported here represents a hitherto undescribed entity. It is thought that both hypertension and brachydactyly are transmitted as an autosomal dominant trait by a single pleiotropic gene or by two closely located genes.
Revista médica de Chile · 2021 · 4 citations · open access
Nuevas perspectivas en el manejo de la hipertensión
AbstractArterial hypertension is one of the biggest public health problems. The research in this area has been relentless and productive, allowing to identify new pathophysiological mechanisms from which new therapeutic options are under development. Despite the recognized efficacy and tolerability of currently available drugs, a high number of patients still do not comply with treatment and maintain inadequate blood pressure levels. This review summarizes the literature about new pharmacological alternatives to treat hypertension. The development state of these new medications ranges from a preclinical state to their clinical use in hypertensive patients. Technological strategies aiming at increasing the compliance with anti-hypertensive medications are also mentioned.
AbstractSome of the important events in the contemporary history of the drug treatment of arterial hypertension are discussed. The many kinds of hypertension are beginning to be recognized and defined, and attempts are being made to fit the treatment to the mechanism. Although only a limited number of mechanisms causing hypertension are involved in the drugs employed, still normal or almost normal blood pressures can be achieved. Physicians and patients must be trained to use these drugs more effectively.
Pharmacological Management of Primary Arterial Hypertension: A Century of Expert Opinions in Cecil Textbook of Medicine.
AbstractBACKGROUND: Advances in drug therapy for primary (or essential) arterial hypertension have contributed to a significant decrease in the frequency and severity of strokes, coronary artery disease and heart failure, and chronic renal insufficiency. STUDY QUESTION: What are the milestones of the changes in the expert approach to the pharmacological management of arterial hypertension in the past century? STUDY DESIGN: To determine the changes in the experts' approach to the management of arterial hypertension, as presented in a widely used textbook in the United States. DATA SOURCES: The chapters presenting the management of arterial hypertension in the 26 editions of Cecil Textbook of Medicine published from 1927 through 2020. RESULTS: The pharmacological management of arterial hypertension has had 3 overlapping eras in the timeframe subject to our investigation. In the empiric era (1927-1947), experts were recommending nonspecific interventions for sedation. The premodern era (1955-1963) relied on ganglion blockers, sympathetic blockers, and direct vasodilators. The modern era (1967-2020), which includes drugs used in current clinical practice, saw the introduction of diuretics (1967), beta-blockers (1971), alpha-blockers (1982), calcium channel blockers (1985), angiotensin-converting enzyme inhibitors (1985), angiotensin receptor blockers (2000), and direct renin inhibitors (2008). CONCLUSIONS: The pharmacological management of arterial hypertension has been the focus of intense and successful research and development in the second half of the 20th century.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
